ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

TLDR AbbVie’s EPS plunges 88%, but Skyrizi and Rinvoq drive revenue growth. Strong immunology sales offset Humira’s drop, keeping AbbVie resilient. Neuroscience shines with Botox and Vraylar boosting double-digit growth. Aesthetics slips as consumer demand cools, weighing on AbbVie margins. AbbVie lifts 2025 EPS outlook and dividend, signaling long-term strength. AbbVie Inc. shares fell 4.45% [...] The post AbbVie Inc. (ABBV) Stock Slides 4.45% as Q3 EPS Plunges 88%, Despite 9% Revenue Growth and Strong Immunology Sales appeared first on CoinCentral.TLDR AbbVie’s EPS plunges 88%, but Skyrizi and Rinvoq drive revenue growth. Strong immunology sales offset Humira’s drop, keeping AbbVie resilient. Neuroscience shines with Botox and Vraylar boosting double-digit growth. Aesthetics slips as consumer demand cools, weighing on AbbVie margins. AbbVie lifts 2025 EPS outlook and dividend, signaling long-term strength. AbbVie Inc. shares fell 4.45% [...] The post AbbVie Inc. (ABBV) Stock Slides 4.45% as Q3 EPS Plunges 88%, Despite 9% Revenue Growth and Strong Immunology Sales appeared first on CoinCentral.

AbbVie Inc. (ABBV) Stock Slides 4.45% as Q3 EPS Plunges 88%, Despite 9% Revenue Growth and Strong Immunology Sales

2025/11/01 04:51

TLDR

AbbVie’s EPS plunges 88%, but Skyrizi and Rinvoq drive revenue growth.
Strong immunology sales offset Humira’s drop, keeping AbbVie resilient.
Neuroscience shines with Botox and Vraylar boosting double-digit growth.
Aesthetics slips as consumer demand cools, weighing on AbbVie margins.
AbbVie lifts 2025 EPS outlook and dividend, signaling long-term strength.

AbbVie Inc. shares fell 4.45% to close at $218.04 after reporting weaker quarterly earnings.

AbbVie Inc., ABBV

The company’s diluted EPS dropped sharply by 88.6% to $0.10 on a GAAP basis. However, total revenues grew 9.1% year over year, driven by solid immunology and neuroscience sales.

Strong Revenue Growth Led by Immunology Portfolio

AbbVie delivered third-quarter net revenues of $15.776 billion, up 9.1% on a reported basis and 8.4% operationally. Immunology remained the company’s top-performing segment, generating $7.885 billion in revenue, up 11.9% year over year. Skyrizi and Rinvoq continued to post strong gains, with Skyrizi revenue surging 46.8% and Rinvoq rising 35.3%.

Humira sales fell 55.4% as biosimilar competition intensified across global markets. Despite the Humira decline, the strong double-digit growth of newer immunology drugs offset losses. AbbVie maintained a dominant position in the immunology market with continued demand for its newer therapies.

Neuroscience and Oncology Portfolios Show Mixed Trends

The neuroscience segment produced $2.841 billion in revenue, a 20.2% increase from the previous year. Vraylar generated $934 million, while Botox Therapeutic brought in $985 million, reflecting rising adoption rates. Additionally, Ubrelvy and Qulipta combined contributed $642 million, supported by strong migraine treatment demand.

The oncology business posted $1.682 billion in quarterly revenue, down 0.3% from last year. Imbruvica fell 14.8% amid competition, though Venclexta rose 7.1% and Elahere gained 23.3%. These trends reflected a balanced oncology portfolio, though Imbruvica’s continued erosion weighed on segment performance.

Aesthetics Segment Declines as Costs Weigh on Earnings

The aesthetics portfolio generated $1.193 billion in revenue, down 3.7% on a reported basis. Botox Cosmetic fell 4.9%, while Juvederm slipped 2.2%, showing weaker consumer demand. Nevertheless, AbbVie retained strong brand recognition in the aesthetics space despite softer market conditions.

On a GAAP basis, operating margin declined to 12.1%, while adjusted margin stood at 30.9%. The company’s acquired IPR&D and milestone expenses negatively impacted results by $1.50 per share. AbbVie reported a high GAAP tax rate of 73.7% and an adjusted tax rate of 24.5%.

Outlook and Dividend Update

AbbVie raised its 2025 adjusted diluted EPS guidance range to $10.61–$10.65, signaling confidence in future earnings strength. The updated forecast includes a $2.05 per-share unfavorable impact from acquired IPR&D and milestone expenses. Moreover, the company announced a 5.5% dividend increase starting February 2026.

Despite near-term profit pressure, AbbVie’s revenue growth and strong portfolio performance underscored its resilient business model. Continued expansion in immunology and neuroscience positions the company for sustained long-term growth. The stock’s sharp decline reflected short-term earnings pressure rather than fundamental weakness.

The post AbbVie Inc. (ABBV) Stock Slides 4.45% as Q3 EPS Plunges 88%, Despite 9% Revenue Growth and Strong Immunology Sales appeared first on CoinCentral.

Market Opportunity

WorldAssets Price(INC)

$0.6723

$0.6723$0.6723

-0.65%

USD

WorldAssets (INC) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.